Literature DB >> 1353342

Phenotypic characteristics of familial Creutzfeldt-Jakob disease associated with the codon 178Asn PRNP mutation.

P Brown1, L G Goldfarb, J Kovanen, M Haltia, F Cathala, M Sulima, C J Gibbs, D C Gajdusek.   

Abstract

A group of 43 patients from seven families affected by Creutzfeldt-Jakob disease (CJD) with the codon 178Asn mutation of the PRNP amyloid precursor gene is compared to a group of 211 patients with the sporadic form of the disease. As a group, the patients with the codon 178Asn mutation had an earlier age at onset of illness (almost always presenting as an insidious loss of memory), a longer duration of illness, and an absence of periodic electroencephalographic activity. Transmission of disease to primates was accomplished using brain tissue homogenates from 6 of 10 patients, resulting in significantly shorter incubation periods than those due to sporadic CJD inocula. These findings are interpreted and discussed in terms of possible differences in the temporospatial evolution of damage to the brain, and of accelerated induction of polymerized amyloid protein by its mutationally altered template precursor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1353342     DOI: 10.1002/ana.410310309

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  14 in total

Review 1.  Genetic PrP Prion Diseases.

Authors:  Mee-Ohk Kim; Leonel T Takada; Katherine Wong; Sven A Forner; Michael D Geschwind
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 2.  Prions, beta-sheets and transmissible dementias: is there still something missing?

Authors:  P P Liberski
Journal:  Acta Neuropathol       Date:  1995       Impact factor: 17.088

3.  Complete penetrance of Creutzfeldt-Jakob disease in Libyan Jews carrying the E200K mutation in the prion protein gene.

Authors:  S Spudich; J A Mastrianni; M Wrensch; R Gabizon; Z Meiner; I Kahana; H Rosenmann; E Kahana; S B Prusiner
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

4.  Fatal familial insomnia and familial Creutzfeldt-Jakob disease: different prion proteins determined by a DNA polymorphism.

Authors:  L Monari; S G Chen; P Brown; P Parchi; R B Petersen; J Mikol; F Gray; P Cortelli; P Montagna; B Ghetti
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-29       Impact factor: 11.205

Review 5.  Alzheimer disease and the prion disorders amyloid beta-protein and prion protein amyloidoses.

Authors:  D L Price; D R Borchelt; S S Sisodia
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-15       Impact factor: 11.205

6.  Familial fatal insomnia with atypical clinical features in a patient with D178N mutation and homozygosity for Met at codon 129 of the prion protein gene.

Authors:  Lin Sun; Xia Li; Xiang Lin; Feng Yan; Kathryn Chen; Shifu Xiao
Journal:  Prion       Date:  2015       Impact factor: 3.931

Review 7.  Genetic prion disease: Experience of a rapidly progressive dementia center in the United States and a review of the literature.

Authors:  Leonel T Takada; Mee-Ohk Kim; Ross W Cleveland; Katherine Wong; Sven A Forner; Ignacio Illán Gala; Jamie C Fong; Michael D Geschwind
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2017-01       Impact factor: 3.568

8.  Prion protein gene analysis in three kindreds with fatal familial insomnia (FFI): codon 178 mutation and codon 129 polymorphism.

Authors:  R Medori; H J Tritschler
Journal:  Am J Hum Genet       Date:  1993-10       Impact factor: 11.025

Review 9.  Spontaneous generation of infectious nucleating amyloids in the transmissible and nontransmissible cerebral amyloidoses.

Authors:  D C Gajdusek
Journal:  Mol Neurobiol       Date:  1994-02       Impact factor: 5.590

Review 10.  A novel mechanism of phenotypic heterogeneity demonstrated by the effect of a polymorphism on a pathogenic mutation in the PRNP (prion protein gene).

Authors:  R B Petersen; L G Goldfarb; M Tabaton; P Brown; L Monari; P Cortelli; P Montagna; L Autilio-Gambetti; D C Gajdusek; E Lugaresi
Journal:  Mol Neurobiol       Date:  1994 Apr-Jun       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.